HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Perrigo Rapped Over Solpadeine Claim in UK, While Cleared Of Wrongdoing In Spanish XLS Ad

Executive Summary

Perrigo has found itself in hot water with the UK's MHRA over claims made on the website of its Solpadeine pain-relief brand. Meanwhile, the company has been exonerated after complaints against a TV ad to promote its XLS weight-loss brand proved to be unfounded.

You may also be interested in...



Ouch! Two UK Analgesic Ad Complaints: Reckitt Rapped, Perrigo Pardoned

Two UK advertising complaint verdicts delivered by the MHRA, Reckitt Benckiser's Nurofen Express (upheld) and Perrigo's Solpadeine Max (not upheld).

UK CBD Limbo Continues – Full List Of ‘Legal’ Products Delayed Until June

A provisional list of CBD products that can continue to legally be sold in the UK has been issued by the Food Standards Agency. However the list currently only includes products from three suppliers and will not be complete until June 2021, meaning the vast majority of companies face a nervy wait.

EU Business Round-Up: Gilbert Grabs Grimberg, Navamedic Adds Brain Health Probiotic, Acino Acquires Russian Portfolio

Latest European consumer health business news: Laboratoires Gilbert strengthens its position in France with Grimberg acquisition; Norway's Navamedic secures distribution of brain health probiotic; and Switzerland's Acino gains two supplements popular in Russia.

Topics

Related Companies

UsernamePublicRestriction

Register

RS149015

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel